Therapeutic EVs
Extracelluar Vesicles, for Drug Development
YM Regen focuses on developing clinically viable extracelluar vesicles, EV-based therapeutics as next-generation drug delivery and treatment platforms. With our patented processes in concentration, purification, and lyophilization, we produce high-purity, bioactive EVs optimized for clinical trials targeting unmet diseases such as acute lung injury and neurodegenerative disorders.
Moving forward, we aim to collaborate with hospitals and regulatory bodies to advance the clinical translation and commercialization of EV-derived pharmaceuticals.